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Abstract
Background
In human immunodeficiency virus treatment adequate virological suppression is warranted,
nevertheless for some patients it remains a challenge. We investigated factors associated
with low-level viraemia (LLV) and virological failure (VF) under combined antiretroviral ther-
apy (cART).
Materials and Methods
We analysed patients receiving standard regimens between 1st July 2012 and 1st July 2013
with at least one viral load (VL) measurement below the quantification limit (BLQ) in their
treatment history. After a minimum of 6 months of unmodified cART, the next single VL mea-
surement within 6 months was analysed. VF was defined as HIV RNA levels200 copies/
mL and all other quantifiable measurements were classified as LLV. Factors associated
with LLV and VF compared to BLQ were identified by logistic regression models.
Results
Of 2276 participants, 1972 (86.6%) were BLQ, 222 (9.8%) showed LLV and 82 (3.6%) had
VF. A higher risk for LLV and VF was shown in patients with cART interruptions and in
patients with boosted PI therapy. The risk for LLV and VF was lower in patients from centres
using the Abbott compared to the Roche assay to measure VL. A higher risk for LLV but not
for VF was found in patients with a higher VL before cART [for >99.999 copies/mL: aOR
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(95% CI): 4.19 (2.07–8.49); for 10.000–99.999 copies/mL: aOR (95% CI): 2.52 (1.23–5.19)]
and shorter cART duration [for <9 months: aOR (95% CI): 2.59 (1.38–4.86)]. A higher risk
for VF but not for LLV was found in younger patients [for <30 years: aOR (95% CI): 2.76
(1.03–7.35); for 30–50 years: aOR (95% CI): 2.70 (1.26–5.79)], people originating from high
prevalence countries [aOR (95% CI): 2.20 (1.09–4.42)] and in male injecting drug users
[aOR (95% CI): 2.72 (1.38–5.34)].
Conclusions
For both VF and LLV, factors associated with adherence play a prominent role. Further-
more, performance characteristics of the diagnostic assay used for VL quantification should
also be taken into consideration.
Introduction
The advent of combined antiretroviral therapy (cART) resulted in a significant reduction in
morbidity and mortality for persons infected with the human immunodeficiency virus type 1
(HIV-1) [1,2]. Suppression of plasma HIV-1 RNA through antiretroviral therapy is the goal of
HIV treatment. Adequate virological suppression also hinders the development of resistance
mutations. Current guidelines define virological suppression below the limit of quantification
of commercial assays which is usually between<20 to 75 copies/mL [3]. On the other hand,
the threshold for virological failure (VF) remains controversial ranging from 50 to 200 copies/
mL [3,4]. These discrepancies reflect the fact that optimal virological suppression remains
often an ideal goal but some patients may show persistent low-level viraemia (LLV) and the
best clinical practice in such cases, especially concerning LLV between 20–200 copies/mL, is
not resolved. Further, the threshold where detectable viral load (VL) in plasma comes from
ongoing replication is not known and remains indistinguishable from circulating virus due to
the release of HIV from latently infected cells.
The objective of this study was to investigate factors associated with LLV defined with a cut-
off<200 copies/mL and VF in a cohort of HIV-1 positive patients.
Methods
Study Design and Data Collection
The Austrian HIV Cohort Study (AHIVCOS) is an open, multicentre, prospective, observa-
tional cohort study of HIV-infected individuals followed at seven HIV treatment centres in
Austria. The study was initiated in 2001 and patients are enrolled actively and prospectively
covering approximately 80% of all treated HIV-infected patients in Austria. Data collection
includes sociodemographic information, complete history of cART as well as laboratory results
with VL and CD4 cell count measurements, usually repeated every 3–6 months. The laboratory
analyses were performed in each single centre and for HIV-1 VL assessment, five centres used
the Roche Cobas AmpliPrep/Cobas TaqMan 2.0 assay (Taqman, Roche Diagnostics, Mann-
heim, Germany), referred to as the Roche assay in this manuscript, while the remaining two
centres used the Abbott RealTime HIV-1 assay (Abbott RT, Abbott Diagnostics, Wiesbaden,
Germany), referred to as the Abbott assay, during the period of time analysed.
Approval for this study was obtained from the local ethical committees of all participating
centres: ethics committee of the Vienna Medical University (No. 898/ 2010), of the Salzburg
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Federal Government (No. 1159/ 2010), of the Graz Medical University (No. 21-431/ 2010), of
the Innsbruck Medical University (No 283/4.4/ 2009), of the Upper Austria Federal Govern-
ment (No C-3-10/ 2010) and of the Carynthian Federal State (No A-13-11/2011). Written
informed consent was given by the patients for their information to be stored in the hospital
database and used for research.
Statistical Analysis
Patient selection. A retrospective analysis was conducted on individuals receiving
unmodified cART for more than 6 months between 1st July 2012 and 1st July 2013 enrolled in
AHIVCOS (N = 4289). Patients who were not on stable cART due to either interruptions or
switches were excluded (N = 290). During these 6 months, patients had to receive cART with 2
nucleoside reverse-transcriptase inhibitors (NRTIs) and either a non-nucleoside reverse-tran-
scriptase inhibitor (NNRTI) or a boosted protease inhibitor (PI) or an integrase inhibitor
(INSTI). Individuals with other cART regimens than those mentioned above, were excluded
(N = 489). A further exclusion criterion was a lacking VL below the respective limit of quantifi-
cation in their treatment history. Thus, another 461 individuals were excluded from analyses
(35 tested with the Abbott assay and 426 with the Taqman assay).
In total, 3049 patients fulfilled the inclusion criteria. 773 patients did not have any VL mea-
surement between 6 and 12 months after initiation of the respective cART regimen and were
too excluded. 2276 patients remained and their first VL measurement between 6 and 12
months after initiation of the respective cART regimen was evaluated.
Definition of LLV and VF. All quantifiable HIV VL measurements below<200 copies/
mL were classified as LLV. For further analyses, LLV was divided into two categories, namely
HIV RNA levels of 51–199 copies/mL and HIV RNA levels of50 copies/mL. VF was defined
as HIV RNA levels 200 copies/mL.
Statistical methods. Groups were compared using χ² test or Fisher´s exact test where
appropriate. To investigate the association between various demographic and clinical parame-
ters with LLV as well as VF compared to BLQ, two separate univariable and multivariable logis-
tic regression models were performed. As reference category for both analyses, patients who
were BLQ at baseline were used (N = 1972). For the first analysis, to find factors associated
with LLV, 82 patients with VF were excluded. 222 (10.1%) of the remaining 2194 patients had
LLV below 200 copies/mL. For the second analysis, to find factors associated with VF, 222
patients who had LLV below 200 copies/mL were excluded. 82 (4.0%) of the remaining 2054
patients had a VF. Variables considered for univariable analyses were age at VL measurement,
HIV transmission category, nationality, CD4 count before cART, ever cART interruptions,
type of VL assay used, diabetes, cART regimen, VL before cART and cART duration. Multivar-
iable models were adjusted for demographic variables age at VL measurement and HIV trans-
mission category whether or not significant in univariable analyses. Further adjustment was
made for variables with p<0.05 in univariable analyses. Ever cART interruptions were defined
as interruptions prior to 6 months of stable cART of the respective cART regimen. A cART dis-
continuation for at least 8 days after having started cART was regarded as cART interruption.
In addition, different sensitivity analyses were performed for different criteria in patient
selection. Another sensitivity analysis was conducted in order to analyse patients´ characteris-
tics stratified by cART regimen. Further, we additionally did an analysis for the two outcomes
LLV and VF excluding the centres measuring VL with the Abbott assay. P-values of<0.05
were considered to indicate statistical significance.
All analyses were conducted using Stata software, version 13.1 (StataCorp, College Station,
TX, USA).
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Results
Patient characteristics stratified by VL
The flowchart of the patient selection is shown in Fig 1 and the characteristics of the 2276
included participants, stratified by HIV RNA levels are listed in Table 1. For all the patients
included in the study, the median age was 43.8 years (interquartile range IQR: 36.6–51.6) and
the majority were men (72.1%). cART was PI-based in 42.9% (976/2276) of the patients, with
darunavir being mostly used. NNRTI- and INSTI-based therapies were used in 57.1% (1300/
2276) of the cases. The median time on cART was 68.4 months (IQR: 32.0–129.8). Seventy
eight percent of the participants had their HIV RNA measured by the Roche assay and 22%
had their HIV RNA measured using the Abbott assay. 773 did not have a VL measurement
within 12 months of respective cART initiation and were excluded. 377 (16.6%) patients had
no prior cART. 1972 of the 2276 included patients were BLQ (86.4%), while 222 (9.8%)
showed a LLV and 82 (3.6%) had VF. Stratification by VL of sociodemographic and labora-
tory analyses showed a higher frequency of male injecting drug users (12.6 and 22.0 versus
8.8%) and of patients with cART interruptions (32.0 and 48.8 versus 24.1%) in the LLV and
VF group compared to patients who were BLQ. PI-based regimens were more frequent (65.9
and 51.4 versus 41.0%). Patients whose HIV RNA was measured by the Roche assay rather
than by the Abbott assay had more quantifiable VL measurements200 copies/mL and
below 200 copies/mL compared to individuals who were BLQ (96.3 and 90.5 versus 75.9%).
A higher VL before cART (>99.999 copies/mL: 50.0% versus 36.9%) was more likely to be
found in patients with LLV. Patients with VF were younger (<30 years: 12.2 versus 8.5%; 30–
50 years: 78.1 versus 64.8%) and more likely originating from high prevalence countries (18.3
versus 8.8%). Concerning VL cases, the majority (35.4%) of the VF cases were below 1000
copies/mL and only 6.1% reached very high VLs (>99.000 copies/mL).
Correlates of LLV
As shown in Table 2, a reduction in risk for LLV was found in female heterosexuals compared
to men who have sex with men [adjusted Odds Ratio, aOR (95% CI): 0.62 (0.41–0.95)] as well
as in patients from 2 centres which used the Abbott assay as compared to the other centres
measuring VL by the Roche assay [aOR (95% CI): 0.33 (0.21–0.51)]. Interrupted cART [aOR
(95% CI): 1.69 (1.22–2.34)] versus uninterrupted cART, 2 NRTIs with a boosted PI as cART
regimen [aOR (95% CI): 1.54 (1.15–2.06)] versus 2 NRTIs with a NNRTI or INSTI, a higher
VL before cART [for>99.999 copies/mL: aOR (95% CI): 4.19 (2.07–8.49); for 10.000–99.999
copies/mL: aOR (95% CI): 2.52 (1.23–5.19); compared to 9.999 copies/mL] and a shorter
cART duration [<9 months: aOR (95% CI): 2.59 (1.38–4.86) compared to>18 months]
increased the risk of LLV.
Correlates of VF
A reduction in risk of VF was found in patients from 2 centres using the Abbott assay as com-
pared to the other centres measuring VL by the Roche assay [aOR (95% CI): 0.09 (0.03–0.30)].
Younger age [for<30 years: aOR (95% CI): 2.76 (1.03–7.35); for 30–50 years: aOR (95% CI):
2.70 (1.26–5.79); compared to>50 years], male intravenous drug users [aOR (95% CI): 2.72
(1.38–5.34)] versus men who have sex with men, originating from high prevalence countries
[aOR (95% CI): 2.20 (1.09–4.42)], interrupted cART [aOR (95% CI): 2.93 (1.84–4.67)] com-
pared to uninterrupted cART and 2 NRTIs with a boosted PI as cART regimen [aOR (95% CI):
2.36 (1.45–3.83)] versus 2 NRTIs with a NNRTI or INSTI increased the risk of VF (Table 2).
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Fig 1. Flowchart of patient selection.
doi:10.1371/journal.pone.0142923.g001
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Table 1. Characteristics of patients stratified by HIV RNA levels below the limit of quantification and low-level viraemia defined as quantifiable HIV
RNA levels <200 copies/mL and virological failure defined as HIV RNA levels200 copies/mL.
All patients BLQ LLV <200 VF 200
No. of patients N = 2276 N = 1972 N = 222 N = 82
N (%) N (%) N (%) N (%) P value1 P value2
Age at VL measurement 0.648 0.002
<30 years 201 (8.8) 168 (8.5) 23 (10.4) 10 (12.2)
30–50 years 1481 (65.1) 1277 (64.8) 140 (63.1) 64 (78.1)
>50 years 594 (26.1) 527 (26.7) 59 (26.6) 8 (9.8)
HIV transmission category 0.034 0.001
Male injecting drug user 220 (9.7) 174 (8.8) 28 (12.6) 18 (22.0)
Female injecting drug user 95 (4.2) 85 (4.3) 5 (2.3) 5 (6.1)
Male heterosexual 477 (21.0) 421 (21.4) 45 (20.3) 11 (13.4)
Female heterosexual 507 (22.3) 448 (22.7) 35 (15.8) 24 (29.3)
Other 98 (4.3) 82 (4.2) 13 (5.9) 3 (3.7)
Men who have sex with men 879 (38.6) 762 (38.6) 96 (43.2) 21 (25.6)
Nationality 0.448 0.004
High prevalence country 212 (9.3) 174 (8.8) 23 (10.4) 15 (18.3)
Low prevalence country 2064 (90.7) 1798 (91.2) 199 (89.6) 67 (81.7)
CD4 count before cART 0.349 0.770
Missing 346 (15.2) 295 (15.0) 39 (17.6) 12 (14.6)
<50 cells/μL 233 (10.2) 207 (10.5) 21 (9.5) 5 (6.1)
50–199 cells/μL 465 (20.4) 399 (20.2) 48 (21.6) 18 (22.0)
200–349 cells/μL 716 (31.5) 615 (31.2) 75 (33.8) 26 (31.7)
350 cells/μL 516 (22.7) 456 (23.1) 39 (17.6) 21 (25.6)
Ever cART interruptions3 0.010 <0.001
1 587 (25.8) 476 (24.1) 71 (32.0) 40 (48.8)
None 1689 (74.2) 1496 (75.9) 151 (68.0) 42 (51.2)
Assay used <0.001 <0.001
Abbott RealTime (2 centres) 501 (22.0) 475 (24.1) 23 (10.4) 3 (3.7)
Roche TaqMan 2.0 (5 centres) 1775 (78.0) 1497 (75.9) 199 (90.5) 79 (96.3)
Ever diabetes4 0.246 0.767
Yes 89 (3.9) 75 (3.8) 12 (5.4) 2 (2.4)
No 2187 (96.1) 1897 (96.2) 210 (94.6) 80 (97.6)
cART regimen 0.003 <0.001
2 NRTIs + PI/r 976 (42.9) 808 (41.0) 114 (51.4) 54 (65.9)
2 NRTIs + NNRTI/INSTI 1300 (57.1) 1164 (59.0) 108 (48.7) 28 (34.2)
VL before cART <0.001 0.746
Missing 406 (17.8) 353 (17.9) 39 (17.6) 14 (17.1)
>99.999 copies/mL 867 (38.1) 728 (36.9) 111 (50.0) 28 (34.2)
10.000–99.999 copies/mL 753 (33.1) 658 (33.4) 63 (28.4) 32 (39.0)
9.999 copies/mL 250 (11.0) 233 (11.8) 9 (4.1) 8 (9.8)
cART duration5 0.056 0.781
<9 months 86 (3.8) 69 (3.5) 15 (6.8) 2 (2.4)
9–18 months 183 (8.0) 158 (8.0) 17 (7.7) 8 (9.8)
>18 months 2007 (88.2) 1745 (88.5) 190 (85.6) 72 (87.8)
First-line cART6 0.949 0.091
Yes 377 (16.6) 332 (16.8) 37 (16.7) 8 (9.8)
(Continued)
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Sensitivity analyses
We performed several sensitivity analyses with different criteria concerning patient selection.
One analysis was performed without considering a VL measurement BLQ in treatment history
in order to exclude patients with very short cART durations. Another analysis was conducted
regarding a shorter recruitment period of 6 months instead of 12 months and one analysis
including patients receiving unmodified cART for>9 months instead of>6 months. All addi-
tional analyses did, however, not reveal any substantial differences in ORs compared to our pri-
mary analysis (data not shown). Stratification of the patients by regimen showed that VL and
age at baseline, HIV transmission category, nationality, CD4 cell count before cART, prior
cART interruptions, assay used and VL before cART differ significantly (see S1 Table). In addi-
tion, sensitivity analyses were conducted for the two outcomes (LLV<200 copies/mL and VF
200 copies/mL) excluding the samples analysed with the Abbott assay. The exclusion of
patients whose VL had been measured by the Abbott assay did not reveal any major changes in
HRs compared to the original models (see S2 Table).
Discussion
This study of well-defined patients on stable cART over a period of more than 6 months gives
insights into the different factors associated with LLV and VF. As expected, adherence-associ-
ated factors play a predominant role. Accordingly, cART interruptions constitute an indepen-
dent risk factor for both LLV and VF, while younger age, the category of male injecting drug
users and originating from high prevalence regions are associated with VF alone. Additionally,
PI-based regimens appear as independent markers for both groups. Several studies have
already shown that NNRTI-based combinations may result in a better suppression of plasma
viral load than PI-based cART [5–7]. On the other hand, we have to acknowledge a potential
clinician induced bias for favorably prescribing PIs in case of suspected adherence issues. We
performed a supplementary stratification of our study patients by regimen and we observed
that patients receiving PIs were found significantly more frequently in the group of intravenous
drug users and in the group originating from high prevalence regions (see S1 Table). In our
study, for first-line therapy, NNRTI-based regimens were the most commonly used (N = 226),
followed by PIs (N = 116). INSTIs were less represented due to recent release during the obser-
vation period (N = 35). However, the majority of our patients were on 2nd or more lines of
Table 1. (Continued)
All patients BLQ LLV <200 VF 200
No. of patients N = 2276 N = 1972 N = 222 N = 82
N (%) N (%) N (%) N (%) P value1 P value2
No 1899 (83.4) 1640 (83.2) 185 (83.3) 74 (90.2)
Abbreviations: LLV, low-level viraemia; VF, virological failure; VL, viral load; NRTIs, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside
reverse transcriptase inhibitor; PI/r, boosted protease inhibitor; INSTI, integrase inhibitor; BLQ, below the limit of quantiﬁcation; cART, combination
antiretroviral therapy;
1 Comparison between quantiﬁable HIV RNA levels <200 copies/mL (LLV) and HIV RNA levels below the limit of quantiﬁcation (BLQ).
2 Comparison between HIV RNA levels 200 copies/mL (VF) and HIV RNA levels below the limit of quantiﬁcation (BLQ).
3 Interruptions prior to 6 months stable cART of the respective cART regimen.
4 Diabetes mellitus prior to 6 months stable cART of the respective cART regimen.
5 cART duration until 6 months stable cART of the respective cART regimen.
6 Whether the respective cART regimen is a ﬁrst-line cART or not.
doi:10.1371/journal.pone.0142923.t001
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Table 2. Univariable andmultivariable logistic regression results: Association between different factors and low-level viraemia as well as virologi-
cal failure compared to HIV RNA levels below the limit of quantification.
Outcome LLV <200 VF 200
No. of patients included N = 2194 N = 2054
No. of outcomes N = 222 N = 82
Univariable Multivariable Univariable Multivariable
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Age at VL measurement
<30 years 1.22 (0.73–2.04) 1.03 (0.60–1.79) 3.92 (1.52–10.10) 2.76 (1.03–7.35)
30–50 years 0.98 (0.71–1.35) 0.97 (0.69–1.35) 3.30 (1.57–6.93) 2.70 (1.26–5.79)
>50 years 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
HIV transmission category
Male injecting drug user 1.28 (0.81–2.01) 1.11 (0.69–1.79) 3.75 (1.96–7.20) 2.72 (1.38–5.34)
Female injecting drug user 0.47 (0.18–1.18) 0.43 (0.17–1.12) 2.13 (0.78–5.81) 1.98 (0.70–5.60)
Male heterosexual 0.85 (0.58–1.23) 0.85 (0.58–1.25) 0.95 (0.45–1.99) 0.79 (0.36–1.72)
Female heterosexual 0.62 (0.41–0.93) 0.62 (0.41–0.95) 1.94 (1.07–3.53) 1.09 (0.55–2.16)
Other 1.26 (0.68–2.34) 1.31 (0.69–2.48) 1.33 (0.39–4.55) 1.30 (0.37–4.56)
Men who have sex with men 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Nationality
High prevalence country 1.19 (0.75–1.89) 2.31 (1.29–4.14) 2.20 (1.09–4.42)
Low prevalence country 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
CD4 count before cART
Missing 1.55 (0.97–2.47) 0.88 (0.43–1.82)
<50 cells/μL 1.19 (0.68–2.07) 0.52 (0.20–1.41)
50–199 cells/μL 1.41 (0.90–2.19) 0.80 (0.51–1.86)
200–349 cells/μL 1.43 (0.95–2.14) 0.92 (0.51–1.65)
350 cells/μL 1.00 (Reference) 1.00 (Reference)
Ever cART interruptions1
1 1.48 (1.09–2.00) 1.69 (1.22–2.34) 2.99 (1.92–4.67) 2.93 (1.84–4.67)
None 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Assay used
Abbott RealTime (2 centres) 0.36 (0.23–0.57) 0.33 (0.21–0.51) 0.12 (0.04–0.38) 0.09 (0.03–0.30)
Roche TaqMan 2.0 (5 centres) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Ever diabetes2
Yes 1.45 (0.77–2.70) 0.63 (0.15–2.62)
No 1.00 (Reference) 1.00 (Reference)
cART regimen
2 NRTIs + PI/r 1.52 (1.15–2.01) 1.54 (1.15–2.06) 2.78 (1.74–4.42) 2.36 (1.45–3.83)
2 NRTIs + NNRTI/INSTI 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
VL before cART
Missing 2.86 (1.36–6.02) 2.70 (1.27–5.76) 1.16 (0.48–2.80)
>99.999 copies/mL 3.95 (1.97–7.91) 4.19 (2.07–8.49) 1.12 (0.50–2.49)
10.000–99.999 copies/mL 2.48 (1.21–5.06) 2.52 (1.23–5.19) 1.42 (0.64–3.12)
9.999 copies/mL 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
cART duration3
<9 months 2.00 (1.12–3.56) 2.59 (1.38–4.86) 0.70 (0.17–2.92)
9–18 months 0.99 (0.59–1.67) 1.00 (0.58–1.73) 1.23 (0.58–2.59)
>18 months 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
(Continued)
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therapy and PIs such as NNRTIs were both equally represented (N = 855 and N = 860, respec-
tively), followed again by INSTIs (N = 184).
Further, the association found between high baseline VL and the risk of developing LLV is in
line with the hypothesis that the size of the cellular compartment infected before cART initiation
determines the level of residual viraemia [6] and is in accordance with other studies [5,8]. Inter-
estingly, the CD4 count before cART start, especially in the very low range of below 50 cells/μl
was comparable in all our 3 groups, BLQ, LLV and VF. This observation argues against the con-
cept that LLV may be more frequent in patients presenting at a late stage of infection.
For our group of patients on stable suppressive therapy, we found a significant risk reduc-
tion for LLV and VF according to the assay used for VL quantification. This finding is interest-
ing since both the Abbott as well as the Roche assays are widely used in clinical settings to
measure HIV RNA and differ significantly regarding their extraction system, primers and
probe design. Although the overall correlation between the Roche and Abbott assay in the
higher range of quantification is good [9,10], significant discrepancies between these assays
have been described at LLV [11–13]. In an international comparative analysis by Swenson
et al., the concordance between four commercial assays including the Roche and Abbott assay
was determined and it was shown that the inter-assay concordance at a threshold of 200 cop-
ies/mL was much higher than at the clinically relevant threshold of 50 copies/mL [14] The pub-
lished literature is controversial concerning the impact of LLV as a predictor of progressive
viral rebound [15–19]. Findings by Ribaudo et al. from a large retrospective analysis found the
same predictive value for virological rebound at an HIV RNA of<200 copies/mL as compared
to a threshold of<50 copies/mL [18]. These discrepancies may be partly explained due to dif-
ferent definitions of LLV and VF but also due to different quantification assays used. The latter
is most problematic since treatment decisions are based on the definitions of VF and virological
suppression, all within the lower range of viraemia. Consecutively, if quantification assays are
not concordant in such settings, a univocal threshold of VF becomes impossible to establish.
Many factors may contribute to such assay discordance, ranging from preanalytic issues, such
as handling procedures, to viral blips or different primer target regions [13,20–25]. In our anal-
ysis, the Roche assay was predominantly used (78% versus 22% Abbott assay) limiting a
Table 2. (Continued)
Outcome LLV <200 VF 200
No. of patients included N = 2194 N = 2054
No. of outcomes N = 222 N = 82
Univariable Multivariable Univariable Multivariable
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
First-line cART4
Yes 0.99 (0.68–1.43) 0.53 (0.26–1.12)
No 1.00 (Reference) 1.00 (Reference)
Abbreviations: LLV, low-level viraemia; VF, virological failure; VL, viral load; CI, conﬁdence interval; OR, odds ratio; NRTIs, nucleoside reverse
transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI/r, boosted protease inhibitor; INSTI, integrase inhibitor; cART,
combination antiretroviral therapy;
1 Interruptions prior to 6 months stable cART of the respective cART regimen.
2 Diabetes mellitus prior to 6 months stable cART of the respective cART regimen.
3 cART duration until 6 months stable cART of the respective cART regimen.
4 Whether the respective cART regimen is a ﬁrst-line cART or not.
doi:10.1371/journal.pone.0142923.t002
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comparative analysis. Additionally, due to the multicentre study design, we cannot rule out dif-
ferent local practices as potential further bias.
Finally, concerned by the high number of patients excluded from our study due to missing
VL assessment within 6 to 12 months (N = 773), we compared patients´ characteristics of the
two groups (data not shown). Individuals excluded differed significantly from included
patients in some factors associated with LLV and/or VF. Excluded patients were significantly
older, males were more frequently infected through injecting drug use and females through
heterosexual contacts. HIV RNA of excluded individuals was more frequently measured by the
Roche assay. On the other hand, VL and CD4 count before cART initiation were significantly
lower and excluded patients had a shorter overall therapy duration, more cART interruptions
and were more frequently on first-line therapy.
In conclusion, the strengths of our study include its large sample size with similar national
standards of care and our results support that adherence associated issues play a central part in
LLV and VF development. The association between PI-based regimens and risk of LLV and VF
remains biased due to confounding by indication. Our data seems to support the concept that
performance characteristics of the diagnostic assay used has to be taken into account for evalu-
ation of LLV and especially in cases where clinical decisions such as therapy switches are pend-
ing. The present study does not yet include clinical follow-up and predictivity. Despite its
observational design, it provides implications for patient management and forms the basis for
future outcome studies. We suggest that similar studies with clinical follow-up including differ-
ent test systems may be able to evaluate the need for guidelines taking into account different
performance characteristics of each assay to establish adequate HIV RNA cutoffs.
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